Reuters logo
BRIEF-Pharnext announces Phase 3 of PXT3003 for treatment of CMT1A
March 16, 2017 / 7:57 PM / 6 months ago

BRIEF-Pharnext announces Phase 3 of PXT3003 for treatment of CMT1A

March 16 (Reuters) - Pharnext SAS:

* Announces initiation of phase 3 extension study PLEO-CMT-FU PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A

* Plans to apply for marketing authorization for PXT3003 in Europe and the United States in Q1 of 2019

* Application should lead to PXT3003 market approval during second half of 2019, as scheduled Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below